TNYA

Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy TN-201 and TN-401 Program Updates on Upcoming Data Readouts and Regulatory Interactions for Pivotal Trial Planning Anticipated by Year-End Current Cash Position Provides Planned Runway into Fourth Quarter 2027 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.

Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Company management will host investor meetings at the upcoming H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026 and the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026.

Tenaya Therapeutics NASDAQ: TNYA expects to provide regulatory and development updates in the fourth quarter for its two cardiac gene therapy programs and its small-molecule candidate TN-301, Chief Financial Officer Eric Hyllengren said during a Canaccord discussion.

Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional Data Releases Plus Updates on Regulatory Discussions on Pivotal Trial Plans for TN-201 and TN-401 Anticipated in 4Q 2026 TN-301 Advancing toward Phase 2 Trial Start in 2H 2027 $10 million Upfront Payment Received from Alnylam Collaboration Extends Cash Runway Through Q3 2027 SOUTH SAN FRANCISCO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that members of management will host 1x1 meetings with investors at the upcoming Canaccord Genuity 46th Annual Growth Conference taking place from August 11-12, 2026 in Boston, Massachusetts.

SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment.

Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise